Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Department of Emergency and Critical Care Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Medicine (Baltimore). 2024 Apr 26;103(17):e37940. doi: 10.1097/MD.0000000000037940.
Sepsis is caused by the body's dysregulated response to infection, which can lead to multiorgan injury and death. Patients with sepsis may develop acute cardiac dysfunction, termed septic cardiomyopathy, which is a global but reversible dysfunction of both sides of the heart. This narrative review discusses the mechanistic changes in the heart during septic cardiomyopathy, its diagnosis, existing treatment options regarding severity and course, and emerging treatment approaches. Although no standardized definition for septic cardiomyopathy exists, it is described as a reversible myocardial dysfunction that typically resolves within 7 to 10 days. Septic cardiomyopathy is often diagnosed based on electrocardiography, cardiac magnetic resonance imaging, biomarkers, and direct invasive and noninvasive measures of cardiac output. Presently, the treatment of septic cardiomyopathy is similar to that of sepsis, primarily focusing on acute interventions. Treatments for cardiomyopathy often include angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and diuretics. However, because of profound hypotension in sepsis, many cardiomyopathy treatments are contraindicated in patients with septic cardiomyopathy. Substantial efforts have been made to study the pathophysiological mechanisms and diagnostic options; however, the lack of a uniform definition for septic cardiomyopathy is challenging for physicians when considering treatments. Another challenge for physicians is that the treatment for septic cardiomyopathy has only focused on acute intervention, whereas the treatment for other cardiomyopathies has been provided on a long-term basis. A better understanding of the underlying mechanisms of septic cardiomyopathy may contribute to the development of a unified definition of the condition and novel treatment options.
脓毒症是由机体对感染的失调反应引起的,可导致多器官损伤和死亡。脓毒症患者可能会出现急性心功能障碍,称为脓毒性心肌病,这是一种双侧心脏的全球性但可逆转的功能障碍。本综述讨论了脓毒性心肌病中心脏的机制变化、其诊断、针对严重程度和病程的现有治疗选择以及新出现的治疗方法。尽管目前尚无脓毒性心肌病的标准化定义,但它被描述为一种可逆性心肌功能障碍,通常在 7 至 10 天内得到解决。脓毒性心肌病通常基于心电图、心脏磁共振成像、生物标志物以及心脏输出的直接有创和无创测量来诊断。目前,脓毒性心肌病的治疗与脓毒症相似,主要侧重于急性干预。心肌病的治疗通常包括血管紧张素转换酶抑制剂、血管紧张素受体阻滞剂和利尿剂。然而,由于脓毒症患者存在严重低血压,许多心肌病治疗方法在患有脓毒性心肌病的患者中是禁忌的。人们已经做出了巨大的努力来研究病理生理机制和诊断选择;然而,脓毒性心肌病缺乏统一的定义,这使得医生在考虑治疗方案时面临挑战。另一个挑战是,脓毒性心肌病的治疗仅侧重于急性干预,而其他心肌病的治疗则是基于长期的。更好地了解脓毒性心肌病的潜在机制可能有助于制定该疾病的统一定义和新的治疗选择。